Laux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Laux has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Hans-Peter Volz
Krankenhaus für Psychiatrie, Psychotherapie und Psychosomatische Medizin Schloss Werneck
3 shared publicationsA. Brunnauer
Kbo-Inn-Salzach-Klinikum
2 shared publicationsAlexander Brunnauer
Kbo-Inn-Salzach-Klinikum gGmbH
2 shared publicationsAnsgar Klimke
Vitos Waldkrankenhaus Köppern
2 shared publications- Alexander Brunnauer
Kbo Inn-Salzach-Klinikum
1 shared publication - Bernhard Widder
Neurowissenschaftliche Gutachtenstelle am Bezirkskrankenhaus Günzburg
1 shared publication
Latest Publications
- 17 September 2026
- Published by Springer Nature
- p. 1-9
Systematik affektiver Störungen
- 21 April 2026
- Published by Springer Nature
- p. 1-6
Psychische Störungen auf Reisen und bei Auslandsaufenthalten
- 21 April 2026
- Published by Springer Nature
- p. 1-6
Psychische Störungen auf Reisen und bei Auslandsaufenthalten
- 18 April 2026
- Published by Springer Nature
- p. 1-4
Übersicht Kliniken, Fachgesellschaften und Dachverbände von Selbsthilfe- und Angehörigengruppen
- 18 April 2026
- Published by Springer Nature
- p. 1-4
Übersicht Kliniken, Fachgesellschaften und Dachverbände von Selbsthilfe- und Angehörigengruppen
- 8 April 2026
- Published by Springer Nature
- p. 1-3
Verzeichnis wichtiger standardisierter Beurteilungsskalen
- 8 April 2026
- Published by Springer Nature
- p. 1-3
Verzeichnis wichtiger standardisierter Beurteilungsskalen
- 7 April 2026
- Published by Springer Nature
- p. 1-2
Wichtige Fachzeitschriften des psychiatrisch-psychotherapeutischen Gebiets
- 7 April 2026
- Published by Springer Nature
- p. 1-2
Wichtige Fachzeitschriften des psychiatrisch-psychotherapeutischen Gebiets
- Open Access
- 1 January 2025
- Published by Wissenschaftliche Verlagsgesellschaft mbH in Psychopharmakotherapie
- Vol. 32 (7) , 1009-1020
Cannabis for Medical Use
In Germany, cannabis is by far the most frequently consumed substance (or mixture of substance) after alcohol and nicotine. Overall, an increase in cannabis use is observed, including problematic use. According to the Epidemiological Survey on Addiction (ESA), 4.5 million adults (8.8%) in Germany used cannabis in 2021. Since April 1, 2024, the new Cannabis Act has been in force in Germany. This is regulated by two new legal bases – the Cannabis for Consumption Act and the Medicinal Cannabis Act. Through partial legalization, cannabis consumption and cannabis use disorders have gained new social significance. It is remarkable that stringent requirements for efficacy and safety otherwise demanded for the approval of medicinal products were waived for cannabis flowers and extracts. The use of cannabis for medical purposes is also subject to controversial discussion in professional circles. Approved indications include spasticity (in multiple sclerosis), loss of appetite in severe wasting diseases, AIDS, nausea and vomiting in the context of chemotherapy, and rare forms of epilepsy. The evidence for efficacy is moderate in the most frequently prescribed indication chronic neuropathic pain. For mental disorders, there are only single case studies and case series. Cannabis-based substances for medical use are generally considered well-tolerated medicinal products. With delta-9-tetrahydrocannabinol (THC)-containing preparations, dizziness and fatigue occur very frequently; with cannabidiol (CBD), very frequent adverse events include reduced appetite, somnolence, diarrhea, vomiting, and elevated liver enzymes. There is a clear association between cannabis use and the development of drug-induced psychoses. In particular, high-dose and long-term cannabis use as well as initiation of use during adolescence can lead to longer-term mental disorders. A recent large umbrella review of meta-analyses (51 RCTs, 50 observational studies) concludes that cannabis is contraindicated in adolescence and young adulthood, as well as in individuals with mental disorders and during pregnancy. Fitness to drive is also not assured. When smoking cannabis flowers, interactions with clozapine, olanzapine, or duloxetine can occur. At the present time, therapy of primary mental disorders with cannabis preparations is neither evidence-based nor in line with guidelines. *Online only English version. The German print version is published as a Review Paper in: Psychopharmakotherapie 2025;32(01):11–24 (DOI: 10.52778/ppt20250006)
- 1 January 2025
- Published by Wissenschaftliche Verlagsgesellschaft mbH in Psychopharmakotherapie
- Vol. 32 (7) , 1009-1020
Open AccessCannabis for Medical Use
In Germany, cannabis is by far the most frequently consumed substance (or mixture of substance) after alcohol and nicotine. Overall, an increase in cannabis use is observed, including problematic use. According to the Epidemiological Survey on Addiction (ESA), 4.5 million adults (8.8%) in Germany used cannabis in 2021. Since April 1, 2024, the new Cannabis Act has been in force in Germany. This is regulated by two new legal bases – the Cannabis for Consumption Act and the Medicinal Cannabis Act. Through partial legalization, cannabis consumption and cannabis use disorders have gained new social significance. It is remarkable that stringent requirements for efficacy and safety otherwise demanded for the approval of medicinal products were waived for cannabis flowers and extracts. The use of cannabis for medical purposes is also subject to controversial discussion in professional circles. Approved indications include spasticity (in multiple sclerosis), loss of appetite in severe wasting diseases, AIDS, nausea and vomiting in the context of chemotherapy, and rare forms of epilepsy. The evidence for efficacy is moderate in the most frequently prescribed indication chronic neuropathic pain. For mental disorders, there are only single case studies and case series. Cannabis-based substances for medical use are generally considered well-tolerated medicinal products. With delta-9-tetrahydrocannabinol (THC)-containing preparations, dizziness and fatigue occur very frequently; with cannabidiol (CBD), very frequent adverse events include reduced appetite, somnolence, diarrhea, vomiting, and elevated liver enzymes. There is a clear association between cannabis use and the development of drug-induced psychoses. In particular, high-dose and long-term cannabis use as well as initiation of use during adolescence can lead to longer-term mental disorders. A recent large umbrella review of meta-analyses (51 RCTs, 50 observational studies) concludes that cannabis is contraindicated in adolescence and young adulthood, as well as in individuals with mental disorders and during pregnancy. Fitness to drive is also not assured. When smoking cannabis flowers, interactions with clozapine, olanzapine, or duloxetine can occur. At the present time, therapy of primary mental disorders with cannabis preparations is neither evidence-based nor in line with guidelines. *Online only English version. The German print version is published as a Review Paper in: Psychopharmakotherapie 2025;32(01):11–24 (DOI: 10.52778/ppt20250006)
- 5 November 2022
- Published by Springer Nature
- p. 1257-1269
Serotonin Reuptake Inhibitors: Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, and Sertraline
- 5 November 2022
- Published by Springer Nature
- p. 1257-1269
Serotonin Reuptake Inhibitors: Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, and Sertraline
- 5 November 2022
- Published by Springer Nature
- p. 1769-1782
Risperidone and Paliperone in the Treatment of Psychosis
- 5 November 2022
- Published by Springer Nature
- p. 1769-1782
Risperidone and Paliperone in the Treatment of Psychosis
- 5 November 2022
- Published by Springer Nature
- p. 1859-1869
Quetiapine in the Treatment of Psychosis